2. World Health Organization, International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Report of a WHO/IDF consultation. Geneva, 2006. URL: https://iris.who.int/bitstream/handle/10665/43588/9241594934_eng.pdf?sequence=1 (date of access – 01.10.2023).

3. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneva, 1999. URL: https://iris.who.int/bitstream/handle/10665/66040/WHO_NCD_ NCS_99.2.pdf?sequence=1&isAllowed=y (date of access – 01.10.2023).

4. Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Eye Study Group and the Action to Control Cardiovascular Risk in Diabetes Follow-On (ACCORDION) Study Group. Persistent effects of intensive glycemic control on retinopathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) follow-on study. Diabetes Care. 2016; 39(7): 1089–100. https://dx.doi.org/10.2337/dc16-0024.

5. Maruthur N.M., Tseng E., Hutfless S. et al. Diabetes medications as monotherapy or metformin- based combination therapy for type 2 diabetes. Ann Intern Med. 2016; 164(11): 740–51. https://dx.doi.org/10.7326/M15-2650.

6. Бирюкова Е.В., Шинкин М.В. Практика сахароснижающей терапии: выбор оптимального препарата из группы ингибиторов дипептидилпептидазы 4. Эффективная фармакотерапия. 2022; 18(6): 20–30.

7. Галстян К.О., Недосугова Л.В., Петунина Н.А. с соавт. Первый отечественный ингибитор ДПП-4 госоглиптин в сравнении с вилдаглиптином при лечении пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2016; 19(1): 89–96.

8. Черникова Н.А., Аметов А.С. Опыт применения российского ингибитора дипептидилпептидазы-4 гозоглиптина. Результаты исследования ОНИКС. Эндокринология: новости, мнения, обучение. 2021; 10(1): 62–69.

9. Phung O.J., Sobieraj D.M., Engel S.S. et al. Early combination therapy for the treatment of type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes, Obes Metab. 2014; 16(5): 410–17. https://dx.doi.org/10.1111/dom.12233.

10. Государственный реестр лекарственных средств Минздрава России. Доступ: http://grls. rosminzdrav.ru (дата обращения – 01.10.2023). State Register of Medicines of the Ministry of Healthcare of Russia. URL: http://grls.rosminzdrav.ru (date of access – 01.10.2023) (In Russ.)].

11. Дедов И.И., Шестакова М.В., Майоров А.Ю. с соавт. «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021; 24(S1): 1–148.

12. Gerstein H.C., Colhoun H.M., Dagenais G.R. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193): 121–30. https://dx.doi.org/10.1016/S0140-6736(19)31149-3.

13. Wiviott S.D., Raz I., Bonaca M.P. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347–57. https://dx.doi.org/10.1056/NEJMoa1812389.

14. Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019; 393(10166): 31–39. https://dx.doi.org/10.1016/S0140-6736(18)32590-X.

15. Zinman B., Wanner C., Lachin J.M. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–28. https://dx.doi.org/10.1056/NEJMoa1504720.

16. Neal B., Perkovic V., Mahaffey K.W. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644–57. https://dx.doi.org/10.1056/NEJMoa1611925.

17. Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375(4): 311–22. https://dx.doi.org/10.1056/NEJMoa1603827.

18. Marso S.P., Bain S.C., Consoli A. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375(19): 1834–44. https://dx.doi.org/10.1056/NEJMoa1607141.

19. Bethel M.A., Patel R.A., Merrill P. et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol. 2018; 6(2): 105–13. https://dx.doi.org/10.1016/S2213-8587(17)30412-6.

20. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol. 2009; 160(6): 909–17. https://dx.doi.org/10.1530/EJE-09-0101.

21. Cannon C.P., Pratley R., Dagogo-Jack S. et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020; 383(15):1 425–35. https://dx.doi.org/10.1056/NEJMoa2004967.

22. Wanner C., Lachin J.M., Inzucchi S.E. et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018; 137(2): 119–29. https://dx.doi.org/10.1161/CIRCULATIONAHA.117.028268.

23. Zelniker T.A., Wiviott S.D., Raz I. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019; 139(17): 2022–31. https://dx.doi.org/10.1161/CIRCULATIONAHA.118.038868.

24. Mann J.F.E., Orsted D.D., Brown-Frandsen K. et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017; 377(9): 839–48. https://dx.doi.org/10.1056/NEJMoa1616011.

25. Gerstein H.C., Colhoun H.M., Dagenais G.R. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019; 394(10193): 131–38. https://dx.doi.org/10.1016/S0140-6736(19)31150-X.